乳腺癌 z-bo 2020-09-21 368

　　Recently, researchers at Boston University School of Medicine (BUSM) discovered genes that play a role in the development of breast cancer into metastatic disease. It can predict the progression of the disease and serve as a target for future breast cancer treatment. Researchers have identified a gene called Serum Depletion Response (SDPR) and the mechanism by which this gene is suppressed or suppressed in breast cancer cells, thereby promoting the spread of tumors. Using models of breast cancer progression, researchers found that invasive and metastatic breast cancer cells have almost no SDPR gene expression. In addition, the overexpression of (or on) this gene in metastatic breast cancer cell models significantly reduces the incidence of metastatic disease.

　　Although advanced technologies have appeared, new tumor metastasis inhibitors (such as SDPR) have been discovered through genome research to prevent breast cancer from spreading to remote areas. BUSM researchers explained in this study that work in this area is mainly a way of regulating epigenetic mechanisms. The current research is to study genes through epigenetic mechanisms (rather than genetic mechanisms), so that cancer cells can easily adapt to the new microenvironment of various human organs far away from the initial location of human cells. Clarified the importance of supervision. according to

　　Researchers said that this study is important because the spread of breast cancer cell metastasis is an important clinical obstacle to treatment. The spread of cancer is the death of breast cancer and other cancer patients. main reason. Samthia Garingham, associate professor of medicine, genetics and genomics, pathology and experimental medicine at Boston University School of Medicine said: "This is very helpful for understanding the underlying molecular mechanisms that promote/prevent cancer metastasis." Very important. "A meta-analysis of computer simulations based on published data showed that tumor samples from bladder cancer, colon cancer, lung cancer, pancreatic cancer, ovarian cancer, and sarcoma also showed lack of expression of SDPR, so it acts as a metastasis suppressor gene.

　　Thiagaringham: "This is a major advance in elucidating the molecular basis of metastatic disease. It may help predict the progression of metastatic cancer, but precise cancer treatments will be developed in the future. It has been determined that the identification of drug targets regulated by SDPR must Through its potential importance."